What development phase is Epontol in?

Epontol is FDA-approved (marketed).

What is the generic name of Epontol?

PROPANIDID is the generic (nonproprietary) name of Epontol.

Last reviewed 2026-04-20 · How we verify

Epontol (PROPANIDID)

FDA-approved withdrawn Small molecule Quality 10/100

Propanidid (Epontol) is a marketed anesthetic agent with a key composition patent expiring in 2028. Its primary competitive advantage lies in its distinct mechanism of action, which differentiates it from off-patent generics like ketamine, etomidate, and propofol. The primary risk is the strong competition from widely available and established generics, which may limit market share and revenue growth.

At a glance

Generic name	PROPANIDID
Drug class	propanidid
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Epontol CI brief — competitive landscape report
Epontol updates RSS · CI watch RSS